SIRPa+ macrophages are increased in patients with FL who progress or relapse after frontline lenalidomide and rituximab.
SIRPa+ macrophages are increased in patients with FL who progress or relapse after frontline lenalidomide and rituximab. Blood Adv. 2022 06 14; 6(11):3286-3293.